SK362692A3 - Expression of specific immunogens by using of virus antigene - Google Patents

Expression of specific immunogens by using of virus antigene Download PDF

Info

Publication number
SK362692A3
SK362692A3 SK3626-92A SK362692A SK362692A3 SK 362692 A3 SK362692 A3 SK 362692A3 SK 362692 A SK362692 A SK 362692A SK 362692 A3 SK362692 A3 SK 362692A3
Authority
SK
Slovakia
Prior art keywords
epitope
protein
hiv
epitopes
virus
Prior art date
Application number
SK3626-92A
Other languages
English (en)
Slovak (sk)
Inventor
Paul P Hung
Shaw-Guang Lin Lee
Narender K Kalyan
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of SK362692A3 publication Critical patent/SK362692A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SK3626-92A 1991-12-11 1992-12-10 Expression of specific immunogens by using of virus antigene SK362692A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80510591A 1991-12-11 1991-12-11

Publications (1)

Publication Number Publication Date
SK362692A3 true SK362692A3 (en) 1995-11-08

Family

ID=25190685

Family Applications (1)

Application Number Title Priority Date Filing Date
SK3626-92A SK362692A3 (en) 1991-12-11 1992-12-10 Expression of specific immunogens by using of virus antigene

Country Status (17)

Country Link
US (1) US5591823A (enExample)
EP (1) EP0546787A3 (enExample)
JP (1) JPH05262667A (enExample)
KR (1) KR930013112A (enExample)
CN (1) CN1073878A (enExample)
AU (1) AU2981992A (enExample)
BR (1) BR9204978A (enExample)
CA (1) CA2084180A1 (enExample)
CZ (1) CZ362692A3 (enExample)
FI (1) FI925590L (enExample)
HU (2) HUT65366A (enExample)
IL (1) IL103928A0 (enExample)
MX (1) MX9207113A (enExample)
NO (1) NO924780L (enExample)
SK (1) SK362692A3 (enExample)
TW (1) TW239162B (enExample)
ZA (1) ZA929355B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0633929T3 (da) * 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
WO1995007099A1 (en) * 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccine and process for producing the same
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
ATE386812T1 (de) * 1995-05-26 2008-03-15 Mg Pmc Llc Methode für die produktion von multivalenten influenza hämagglutinin vakzinen
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
WO1998048834A1 (en) * 1997-04-30 1998-11-05 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
WO2002026252A1 (en) * 2000-08-10 2002-04-04 Tsinghua University A vaccine for influenza virus and its preparation
ATE281318T1 (de) 2000-09-11 2004-11-15 Dow Global Technologies Inc Herstellungsverfahren eines reifenstützkörpers
JP2007524609A (ja) * 2003-04-10 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド コンフォメーションに関する変種のプロファイリング、抗体組成物
MX2007015105A (es) * 2005-06-01 2008-03-18 Variation Biotechnologies Inc Formulacion de vacuna de influenza a base de peptido.
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP3058954B1 (en) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CN104086625B (zh) 2008-10-22 2016-08-31 肿瘤疗法科学股份有限公司 Rab6kifl/kif20a表位肽及包含它的疫苗
CN101708442B (zh) * 2009-09-04 2011-08-24 山东中惠仪器有限公司 全自动标准气体配制装置
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10291197B2 (en) 2016-02-03 2019-05-14 Cg Discovery, Inc. Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
EP0492920A1 (en) * 1990-12-24 1992-07-01 Merck & Co. Inc. Chimaeric influenza-HIV vaccine

Also Published As

Publication number Publication date
US5591823A (en) 1997-01-07
FI925590A7 (fi) 1993-06-12
HU211548A9 (en) 1995-12-28
ZA929355B (en) 1994-06-02
NO924780L (no) 1993-06-14
BR9204978A (pt) 1993-06-15
TW239162B (enExample) 1995-01-21
FI925590A0 (fi) 1992-12-09
NO924780D0 (no) 1992-12-10
FI925590L (fi) 1993-06-12
CZ362692A3 (en) 1994-02-16
JPH05262667A (ja) 1993-10-12
HUT65366A (en) 1994-05-02
AU2981992A (en) 1993-06-17
HU9203931D0 (en) 1993-04-28
KR930013112A (ko) 1993-07-21
CA2084180A1 (en) 1993-06-12
IL103928A0 (en) 1993-04-04
EP0546787A2 (en) 1993-06-16
CN1073878A (zh) 1993-07-07
MX9207113A (es) 1994-05-31
EP0546787A3 (en) 1994-06-01

Similar Documents

Publication Publication Date Title
SK362692A3 (en) Expression of specific immunogens by using of virus antigene
Brennan et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus
RU2201421C2 (ru) Синтетический пептид hiv (варианты), иммуногенная композиция для индукции иммунного ответа против пептидов hiv, диагностический набор для определения hiv-специфичных антител
JP3871708B2 (ja) 抗原的に標識した非感染性レトロウィルス様粒子
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
AU4704899A (en) Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders
IE921875A1 (en) Vaccine and treatment method for human immunodeficiency¹virus
JP2000253876A (ja) センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
KR102077876B1 (ko) Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물
US12397050B2 (en) Universal mammalian influenza vaccine
CA2171544C (en) Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains
JPH07505412A (ja) Ｃｔｌ応答の誘導
Kalyan et al. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1
AU731706B2 (en) Recombinant viral pseudo-particles and vaccinal and antitumoral applications thereof
Weijer et al. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene
US9796773B2 (en) Neutralizing antibodies that bind to the HIV-1 Env V2 critical neutralization domain
EP0328390B1 (en) Peptide treatment of refractory infectious diseases
Kelker et al. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
JPH09500096A (ja) ヒト免疫不全ウイルスに対する予防接種および中和抗体誘発に用いられるペプチド
EP1324770A2 (en) Non-replicative particulate vaccine delivery system and methods of making and using same
JP4317912B2 (ja) エイズワクチン
JP2001505763A (ja) Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
Moynier et al. Characterization of humoral immune responses induced by immunization with plasmid DNA expressing HIV-1 Nef accessory protein